Coppell Advisory Solutions LLC Buys 27,037 Shares of Omnicell, Inc. $OMCL

Key Points

• Coppell Advisory Solutions LLC increased its stake in Omnicell, Inc. by 5,343.3% during Q1, owning approximately 0.06% of the company, valued at $1.05 million.
• Omnicell's EPS for the last quarter was reported at $0.45, exceeding analysts' estimates of $0.30, with revenue of $290.56 million, showing a 5.0% increase compared to the same quarter last year.
• Analysts currently have a consensus rating of "Moderate Buy" for Omnicell, with a price target averaging $46.71, after several analyst revisions on price targets and ratings.

Coppell Advisory Solutions LLC grew its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 5,343.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,543 shares of the company's stock after buying an additional 27,037 shares during the period. Coppell Advisory Solutions LLC owned 0.06% of Omnicell worth $1,053,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Principal Financial Group Inc. raised its position in shares of Omnicell by 2.6% in the first quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock valued at $8,553,000 after purchasing an additional 6,288 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Omnicell in the 1st quarter valued at about $2,073,000. Jane Street Group LLC raised its holdings in Omnicell by 7.4% in the 4th quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock valued at $2,417,000 after acquiring an additional 3,725 shares during the period. GSA Capital Partners LLP acquired a new stake in Omnicell during the first quarter worth approximately $901,000. Finally, EP Wealth Advisors LLC bought a new stake in shares of Omnicell during the first quarter worth approximately $245,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on OMCL. Piper Sandler lowered their target price on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Bank of America increased their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Wells Fargo & Company upped their price target on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, Omnicell has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Price Performance

Shares of NASDAQ OMCL traded down $1.45 during mid-day trading on Friday, reaching $31.83. The company had a trading volume of 492,448 shares, compared to its average volume of 500,188. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 63.66, a PEG ratio of 7.27 and a beta of 0.82. The business's 50-day simple moving average is $30.71 and its 200 day simple moving average is $31.05. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the firm earned $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, research analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.